Dr. Jordan Gauthier explains his findings on a combination immunotherapy treatment. Gauthier and his team found that adding the targeted therapy drug ibrutinib to CAR T-cell therapy led to improved responses in patients with relapsed/refractory chronic lymphocytic leukemia.
Dr. Jonathan Wright discusses the available therapies for patients with localized muscle-invasive bladder cancer which include neoadjuvant chemotherapy, upfront cystectomy and immunotherapy.
Dr. Gary Gilliland, Fred Hutch president and director, comments on the newly-announced Allen Institute for Immunology, which includes a research collaboration with Fred Hutch.
Alex Salter, a graduate student working in Stan Riddell's lab, made the Forbes 30 under 30 healthcare list for his work in immunotherapy.
Dr. Seth M. Pollack, a sarcoma expert at Fred Hutch, talks about the potential for – and the challenges in – creating vaccines to treat and prevent cancer. “There almost certainly is not a universal target. The vaccine has to tell the immune system to go find something specific, but there’s nothing specific that the immune system can look for that is common to all cancers,” he said, adding that “there are some targets that are expressed by lots of cancers.”
FierceBiotech highlighted work conducted by Dr. Kristin Anderson in Dr. Phil Greenberg’s lab on immunotherapy in ovarian cancer. The results, which were presented at the 2019 American Association for Cancer Research annual meeting showed that when combining engineered T cells with two other immune boosting treatments, the growth of ovarian tumors in mice was decreased.
Q&A with Fred Hutch immunotherapy researcher Dr. Aude Chapuis
Quotes Hutch immunotherapy researcher Dr. David Maloney about promising new clinical trial results published today reporting 27 out of 29 leukemia patients having no detectable signs of disease
Article about advances in immunotherapy mentions the research of Fred Hutch's Dr. Phil Greenberg as well as spinoff biotech company Juno Therapeutics
Article about the cancer moonshot and immunotherapy mentions Drs. Paul Nghiem and Shailender Bhatia, who are part of the Cancer Immunotherapy Trials Network, which is based at Fred Hutch